Lotus Pharmaceuticals, Inc. (OTCBB: LTUS) reported that its isosorbide mononitrate sustained release tablet, a generic version of angina drug Imdur from AstraZeneca (NYSE: AZN), produced positive results in a clinical trial. Data from the trial were not released, but promised. Lotus expects to submit the drug to the SFDA and, if approved, launch it in 2009. We look at the drug and at Lotus.  More details...

Stock Symbol: (OTCBB: LTUS) (NYSE: AZN)